According to AMC2 MED.B.090, what must be arranged for an appropriate period of time for applicants with a malignant disease?

Arrangements for an oncological follow-up must be made for an appropriate period of time.

What does AMC2 MED.B.090 state about the evidence of residual malignant disease after primary treatment?

It states that after primary treatment, there must be no evidence of residual malignant disease likely to jeopardise flight safety.

Under AMC2 MED.B.090, what is the requirement regarding time elapsed after primary treatment for a malignant disease?

Time appropriate to the type of tumour and primary treatment must have elapsed.

For applicants with pre-malignant skin conditions, what two conditions must be met to be assessed as fit?

The conditions must be treated or excised as necessary, and there must be a regular follow-up.

AMC2 MED.B.090 Oncology

Q: Under AMC2 MED.B.090, what conditions must be met for an applicant diagnosed with a malignant disease to be considered for a fit assessment?

The applicant may be considered for a fit assessment provided that: (1) after primary treatment, there is no evidence of residual malignant disease likely to jeopardise flight safety; (2) time appropriate to the type of tumour and primary treatment has elapsed; (3) the risk of in-flight incapacitation from a recurrence or metastasis is sufficiently low; (4) there is no evidence of short or long-term sequelae from treatment that may jeopardise flight safety; and (5) arrangements for an oncological follow-up have been made for an appropriate period of time.

Q: In the context of oncology assessments under AMC2 MED.B.090, what specific requirement addresses the risk of in-flight incapacitation?

The requirement is that the risk of in-flight incapacitation from a recurrence or metastasis is sufficiently low.

Q: What does AMC2 MED.B.090 say about sequelae from treatment for a malignant disease?

There must be no evidence of short or long-term sequelae from treatment that may jeopardise flight safety.

Navigate / EASA

Ask question Discover more Add to collection

AMC2 MED.B.090 Oncology

ED Decision 2019/002/R

(a) Applicants who have been diagnosed with a malignant disease may be considered for a fit assessment provided that:

(1) after primary treatment, there is no evidence of residual malignant disease likely to jeopardise flight safety;

(2) time appropriate to the type of tumour and primary treatment has elapsed;

(3) the risk of in-flight incapacitation from a recurrence or metastasis is sufficiently low;

(4) there is no evidence of short or long-term sequelae from treatment that may jeopardise flight safety;

(5) arrangements for an oncological follow-up have been made for an appropriate period of time.

(b) Applicants receiving ongoing chemotherapy or radiation treatment should be assessed as unfit.

(c) Applicants with pre-malignant conditions of the skin may be assessed as fit if treated or excised as necessary and there is a regular follow-up.

Details

Source-Title: AMC2 MED.B.090 Oncology View latest amendments

Erulesid: ERULES-1963177438-11277 Compare versions

Domain: Aircrew

Applicabilitydate: 30 January, 2019

Entryintoforcedate: 29 January, 2019

Regulatorysource: ED Decision 2019/002/R Navigate

Regulatorysubject: Part-MED

Typeofcontent: AMC to IR (Acceptable means of compliance to implementing rule)

Parentir: MED.B.090 Oncology

Origin: EASA

Category: EAR